Open Access

Clinical efficacy of apatinib in treating metastatic gastric cancer and its effect on IL‑17

  • Authors:
    • Ran Chen
    • Qi‑Tian Chen
    • You‑Hong Dong
  • View Affiliations

  • Published online on: April 18, 2019     https://doi.org/10.3892/ol.2019.10270
  • Pages: 5447-5452
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Clinical efficacy of apatinib in treating metastatic gastric cancer and its effect on the levels of serum IL‑17 were investigated. A retrospective analysis was performed on 129 patients who had metastatic gastric cancer after first‑line chemotherapy and were treated in Xiangyang No. 1 People's Hospital from February 2012 to February 2015. Of these patients, 78 received oral apatinib and were assigned to experimental group; and 51 received oral tegafur‑gimeracil‑oteracil and were assigned to control group. Clinical efficacy was compared between the two groups, and the levels of serum IL‑17 were measured for all the patients. The treatment response rate in the experimental group was 52.56% and in the control group 31.37%. Apparently, the treatment response rate in the experimental group was higher than that in the control group, and the difference was statistically significant (P<0.05). The incidence of adverse drug reactions in the experimental group was significantly lower than that in the control group (P<0.05). The serum level of IL‑17 after one course of medication was significantly lower than that before medication in both groups (P<0.05). In comparison between groups, the serum level of IL‑17 after one course of medication was clearly lower in the experimental group than that in the control group (P<0.05). Apatinib regimen was demonstrated to have less toxic side‑effects in the treatment of metastatic gastric cancer than tegafur‑gimeracil‑oteracil regimen, indicating that apatinib has favorable safety. In addition, apatinib can downregulate IL‑17 expression, which is helpful in attenuating tumor proliferation and improving the clinical efficacy. Therefore, apatinib has potential use in a wide range of clinical applications.
View Figures
View References

Related Articles

Journal Cover

June 2019
Volume 17 Issue 6

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Chen, R., Chen, Q., & Dong, Y. (2019). Clinical efficacy of apatinib in treating metastatic gastric cancer and its effect on IL‑17. Oncology Letters, 17, 5447-5452. https://doi.org/10.3892/ol.2019.10270
MLA
Chen, R., Chen, Q., Dong, Y."Clinical efficacy of apatinib in treating metastatic gastric cancer and its effect on IL‑17". Oncology Letters 17.6 (2019): 5447-5452.
Chicago
Chen, R., Chen, Q., Dong, Y."Clinical efficacy of apatinib in treating metastatic gastric cancer and its effect on IL‑17". Oncology Letters 17, no. 6 (2019): 5447-5452. https://doi.org/10.3892/ol.2019.10270